Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
J Med Chem
2012 Jan 12;551:327-41. doi: 10.1021/jm201230z.
Show Gene links
Show Anatomy links
Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors.
Irvine MW, Costa BM, Dlaboga D, Culley GR, Hulse R, Scholefield CL, Atlason P, Fang G, Eaves R, Morley R, Mayo-Martin MB, Amici M, Bortolotto ZA, Donaldson L, Collingridge GL, Molnár E, Monaghan DT, Jane DE.
???displayArticle.abstract???
Competitive N-methyl-d-aspartate receptor (NMDAR) antagonists bind to the GluN2 subunit, of which there are four types (GluN2A-D). We report that some N(1)-substituted derivatives of cis-piperazine-2,3-dicarboxylic acid display improved relative affinity for GluN2C and GluN2D versus GluN2A and GluN2B. These derivatives also display subtype selectivity among the more distantly related kainate receptor family. Compounds 18i and (-)-4 were the most potent kainate receptor antagonists, and 18i was selective for GluK1 versus GluK2, GluK3 and AMPA receptors. Modeling studies revealed structural features required for activity at GluK1 subunits and suggested that S674 was vital for antagonist activity. Consistent with this hypothesis, replacing the equivalent residue in GluK3 (alanine) with a serine imparts 18i antagonist activity. Antagonists with dual GluN2D and GluK1 antagonist activity may have beneficial effects in various neurological disorders. Consistent with this idea, antagonist 18i (30 mg/kg ip) showed antinociceptive effects in an animal model of mild nerve injury.
???displayArticle.pubmedLink???
22111545 ???displayArticle.pmcLink???PMC3269097 ???displayArticle.link???J Med Chem ???displayArticle.grants???[+]
Alushin,
Binding site and ligand flexibility revealed by high resolution crystal structures of GluK1 competitive antagonists.
2011, Pubmed
Alushin,
Binding site and ligand flexibility revealed by high resolution crystal structures of GluK1 competitive antagonists.
2011,
Pubmed Anderson,
Capabilities of the WinLTP data acquisition program extending beyond basic LTP experimental functions.
2007,
Pubmed Atlason,
Mapping the ligand binding sites of kainate receptors: molecular determinants of subunit-selective binding of the antagonist [3H]UBP310.
2010,
Pubmed Bettler,
Cloning of a novel glutamate receptor subunit, GluR5: expression in the nervous system during development.
1990,
Pubmed
,
Xenbase Bortolotto,
Kainate receptors are involved in synaptic plasticity.
1999,
Pubmed Bortolotto,
Synaptic plasticity in the hippocampal slice preparation.
2011,
Pubmed Buller,
Pharmacological heterogeneity of NMDA receptors: characterization of NR1a/NR2D heteromers expressed in Xenopus oocytes.
1997,
Pubmed
,
Xenbase Buller,
The molecular basis of NMDA receptor subtypes: native receptor diversity is predicted by subunit composition.
1994,
Pubmed
,
Xenbase Cheng,
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
1973,
Pubmed Clarke,
A hippocampal GluR5 kainate receptor regulating inhibitory synaptic transmission.
1997,
Pubmed Collingridge,
A nomenclature for ligand-gated ion channels.
2009,
Pubmed Costa,
N-methyl-D-aspartate (NMDA) receptor NR2 subunit selectivity of a series of novel piperazine-2,3-dicarboxylate derivatives: preferential blockade of extrasynaptic NMDA receptors in the rat hippocampal CA3-CA1 synapse.
2009,
Pubmed
,
Xenbase Costa,
A novel family of negative and positive allosteric modulators of NMDA receptors.
2010,
Pubmed
,
Xenbase Dolman,
Structure-activity relationship studies on N3-substituted willardiine derivatives acting as AMPA or kainate receptor antagonists.
2006,
Pubmed Dolman,
Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors.
2005,
Pubmed Dominguez,
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain.
2005,
Pubmed Durand,
Cloning of an apparent splice variant of the rat N-methyl-D-aspartate receptor NMDAR1 with altered sensitivity to polyamines and activators of protein kinase C.
1992,
Pubmed
,
Xenbase Durocher,
High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells.
2002,
Pubmed Evans,
A comparison of excitatory amino acid antagonists acting at primary afferent C fibres and motoneurones of the isolated spinal cord of the rat.
1987,
Pubmed Feng,
Structure-activity analysis of a novel NR2C/NR2D-preferring NMDA receptor antagonist: 1-(phenanthrene-2-carbonyl) piperazine-2,3-dicarboxylic acid.
2004,
Pubmed
,
Xenbase Filla,
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
2002,
Pubmed Fischer,
Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro.
1997,
Pubmed
,
Xenbase Hargreaves,
A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.
1988,
Pubmed Hizue,
Involvement of N-methyl-D-aspartate-type glutamate receptor epsilon1 and epsilon4 subunits in tonic inflammatory pain and neuropathic pain.
2005,
Pubmed Hoo,
Functional expression and pharmacological characterization of the human EAA4 (GluR6) glutamate receptor: a kainate selective channel subunit.
1994,
Pubmed Hulse,
Characterization of a novel neuropathic pain model in mice.
2008,
Pubmed Jane,
Kainate receptors: pharmacology, function and therapeutic potential.
2009,
Pubmed Kalia,
NMDA receptors in clinical neurology: excitatory times ahead.
2008,
Pubmed Kerchner,
Kainate receptor subunits underlying presynaptic regulation of transmitter release in the dorsal horn.
2002,
Pubmed Kew,
Ionotropic and metabotropic glutamate receptor structure and pharmacology.
2005,
Pubmed Kinarsky,
Identification of subunit- and antagonist-specific amino acid residues in the N-Methyl-D-aspartate receptor glutamate-binding pocket.
2005,
Pubmed
,
Xenbase Klapars,
Copper-catalyzed halogen exchange in aryl halides: an aromatic Finkelstein reaction.
2002,
Pubmed Korczak,
cDNA cloning and functional properties of human glutamate receptor EAA3 (GluR5) in homomeric and heteromeric configuration.
1995,
Pubmed Lucifora,
Presynaptic low- and high-affinity kainate receptors in nociceptive spinal afferents.
2006,
Pubmed Mayer,
Crystal structures of the kainate receptor GluR5 ligand binding core dimer with novel GluR5-selective antagonists.
2006,
Pubmed
,
Xenbase Molnár,
Biochemical and immunocytochemical characterization of antipeptide antibodies to a cloned GluR1 glutamate receptor subunit: cellular and subcellular distribution in the rat forebrain.
1993,
Pubmed More,
Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist.
2004,
Pubmed Morley,
Synthesis and pharmacology of N1-substituted piperazine-2,3-dicarboxylic acid derivatives acting as NMDA receptor antagonists.
2005,
Pubmed
,
Xenbase Mosley,
Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists.
2010,
Pubmed
,
Xenbase Neyton,
Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach.
2006,
Pubmed Nutt,
Molecular characterization of the human EAA5 (GluR7) receptor: a high-affinity kainate receptor with novel potential RNA editing sites.
1994,
Pubmed O'Neill,
LY377770, a novel iGlu5 kainate receptor antagonist with neuroprotective effects in global and focal cerebral ischaemia.
2000,
Pubmed O'Neill,
Decahydroisoquinolines: novel competitive AMPA/kainate antagonists with neuroprotective effects in global cerebral ischaemia.
1998,
Pubmed Perrais,
Antagonism of recombinant and native GluK3-containing kainate receptors.
2009,
Pubmed Pook,
A comparison of the actions of agonists and antagonists at non-NMDA receptors of C fibres and motoneurones of the immature rat spinal cord in vitro.
1993,
Pubmed Sanacora,
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.
2008,
Pubmed SCHULTZ,
Attempts to find new antimalarials; derivatives of phenanthrene; amino alcohols derived from 9-chlorophenanthrene.
1946,
Pubmed Sheardown,
2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: a neuroprotectant for cerebral ischemia.
1990,
Pubmed Simmons,
Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat.
1998,
Pubmed Smolders,
Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures.
2002,
Pubmed Summers,
Hydroxamic acid inhibitors of 5-lipoxygenase.
1987,
Pubmed Traynelis,
Glutamate receptor ion channels: structure, regulation, and function.
2010,
Pubmed Vignes,
The GluR5 subtype of kainate receptor regulates excitatory synaptic transmission in areas CA1 and CA3 of the rat hippocampus.
1998,
Pubmed Watkins,
The glutamate story.
2006,
Pubmed Weiss,
Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo.
2006,
Pubmed Wendt,
Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.
2004,
Pubmed Wilding,
Functional diversity and developmental changes in rat neuronal kainate receptors.
2001,
Pubmed
